Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 23;5(22):4560-4568.
doi: 10.1182/bloodadvances.2021004999.

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials

Chezi Ganzel  1 , Ju-Whei Lee  2 , Hugo F Fernandez  3 , Elisabeth M Paietta  4 , Selina M Luger  5 , Hillard M Lazarus  6 , Larry D Cripe  7 , Dan Douer  8 , Peter H Wiernik  9 , Jacob M Rowe  10 , Martin S Tallman  11 , Mark R Litzow  12
Affiliations

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials

Chezi Ganzel et al. Blood Adv. .

Abstract

Central nervous system (CNS) involvement in patients with newly diagnosed acute myeloid leukemia (AML) is rare, and systematic data regarding outcome are scarce. This retrospective study summarized data from 11 consecutive Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) clinical trials for patients with newly diagnosed AML. In all, 3240 patients with AML were analyzed, and 36 (1.11%) were found to have CNS involvement at diagnosis. The incidence of CNS disease among the 5 studies with per protocol mandatory lumbar puncture (LP) was similar to the incidence among studies in which LP was performed at the discretion of the investigator (0.86% vs 1.41%; P = .18). There was no significant difference in the rate of complete remission (CR) among patients with CNS involvement and those with other extramedullary disease (EMD) sites or those with no EMD (52.8% vs 59.3%-60%). The median overall survival (OS) for patients who were CNS positive, who had other EMD, or who had no EMD was 11.4, 11.3, and 12.7 months, respectively. There was no difference in OS among patients with CNS involvement, those with other EMD (hazard ratio [HR], 0.96; adjusted P = .84), and those with no EMD (HR, 1.19; adjusted P = .44). In conclusion, the reported incidence of CNS involvement in patients with newly diagnosed AML is low (1.1%), irrespective of whether an LP is mandatory or not. The presence of CNS disease at diagnosis in and of itself does not seem to portend a poor prognosis for achieving an initial CR or for OS.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
OS of the 3 patient groups: CNS-positive, other EMD, no EMD.
See this image and copyright information in PMC

References

    1. Muss HB, Moloney WC.. Chloroma and other myeloblastic tumors. Blood. 1973;42(5):721-728. - PubMed
    1. Chang H, Brandwein J, Yi QL, Chun K, Patterson B, Brien B.. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res. 2004;28(10):1007-1011. - PubMed
    1. Tallman MS, Kim HT, Paietta E, et al. ; Eastern Cooperative Oncology Group . Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22(7):1276-1286. - PubMed
    1. Tallman MS, Hakimian D, Shaw JM, Lissner GS, Russell EJ, Variakojis D.. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol. 1993;11(4):690-697. - PubMed
    1. Byrd JC, Weiss RB, Arthur DC, et al. . Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997;15(2):466-475. - PubMed

Publication types

MeSH terms